TXG10x Genomics, Inc.
Laboratory Analytical Instruments
- Revenue
- $643M
- 5.2% YoY
- Operating margin
- -9.5%
- 70% YoY
- EBITDA
- −$25M
- 84% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$314M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired17% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear1% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $490M | $516M | $619M | $611M | $643M | 5.2% |
| Operating income | −$52M | −$168M | −$265M | −$195M | −$61M | 69% |
| Net income | −$58M | −$166M | −$255M | −$183M | −$44M | 76% |
| Operating cash flow | −$21M | −$34M | −$15M | $7M | $136M | 1942% |
| Capex | $101M | $132M | $49M | $12M | $6M | 52% |
| Stock-based comp | $96M | $137M | $167M | $141M | $109M | 22% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $7M · 16
- Net
- −$7M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $6M | $7M | 12 | 125 |
| FY2024 | $8M | −$21M | 10 | 93 |
| FY2023 | $8M | $17M | 40 | 94 |
| FY2022 | $19M | −$14M | 26 | 90 |
| FY2021 | $12M | $21M | 105 | 100 |